Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price rose 6.2% during mid-day trading on Tuesday . The stock traded as high as $12.63 and last traded at $12.59. Approximately 81,641 shares were traded during trading, a decline of 70% from the average daily volume of 269,682 shares. The stock had previously closed at $11.85.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a report on Monday, March 31st. One analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.
Check Out Our Latest Stock Report on Mesoblast
Mesoblast Stock Performance
The company has a fifty day simple moving average of $11.22 and a two-hundred day simple moving average of $14.02. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.
Hedge Funds Weigh In On Mesoblast
Several institutional investors have recently bought and sold shares of the stock. Barclays PLC bought a new position in shares of Mesoblast in the fourth quarter worth about $38,000. Lindbrook Capital LLC increased its stake in shares of Mesoblast by 70.9% in the fourth quarter. Lindbrook Capital LLC now owns 2,172 shares of the company's stock worth $43,000 after purchasing an additional 901 shares during the period. JPMorgan Chase & Co. bought a new position in shares of Mesoblast in the fourth quarter worth about $50,000. BNP Paribas Financial Markets increased its stake in shares of Mesoblast by 86,566.7% in the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock worth $51,000 after purchasing an additional 2,597 shares during the period. Finally, Tower Research Capital LLC TRC bought a new position in shares of Mesoblast in the fourth quarter worth about $88,000. 1.43% of the stock is currently owned by institutional investors.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
